Category: Featured

Featured posts

HY Medical AI and You’an Hospital join forces in the battle against NCP

Professor Li Hongjun, Chairman of the Professional Committee of Infectious Disease Radiology of the Chinese Medical Association Radiology Branch and Director of the Department of Radiology of You’an Hospital, along with members of the committee worked through the Spring Festival holidays, racing against time to launch the first “Handbook of Medical Imaging Diagnosis of NCP” (English and Chinese Edition). Under the leadership of Director Li Hongjun, You’an hospital continues to fight the battle to defend the public health. Recently, HY Medical’s NCP AI imaging intelligent solution has been stationed in You’an Hospital, bringing practical intelligent assistance to the complete process of screening, diagnosis and treatment of the NPC epidemic.

HY Medical: How will AI join forces in the battle against NCP?

The coronavirus infection, also known as COVID-19, hit with a relentless fury since its initial outbreak in Wuhan, China. As of Feb 24, 2020, there have been 2,000 reported deaths out of 70,000 infected so far.

Medical imaging plays a crucial role in the diagnosis and treatment of Novel Coronavirus Pneumonia (NCP), from early discovery of lung abnormalities in suspect cases, to confirming diagnosis and/or determining level of progression, from excluding suspect cases through differential diagnosis, to forming and adjusting treatment plans, as well as tracking conditional development and evaluating the final treatment efficacy and outcome.

“Real” AI for real assistance, Fight the epidemic hand in hand

Starting with the algorithm, the HY Medical team collected large amounts of NPC data in real time and obtained precise labelling from a professional panel of doctors to use as the base for their deep learning algorithm. The HY Medical AI system automatically adapts to images from different hospitals, different equipment, and different layer thicknesses, as well as apply self-iteration and model optimizations. The detection and accuracy rate of NPC lesions have reached 96%; combined with technologies such as efficient processors and lightweight network models, it only takes 2-3 seconds to process a CT study with 500 images.

According to on-site personnel, “CT data is but a collection of values used to describe density, CT values alone will not help in determining the various types of indicators in data. Selecting precise labeled data + deep learning algorithm can help demarcate each individual lesion, providing precise contour and volume. AI products play a key role in assisting doctors with their diagnosis, its ability to accurately pin-point the position and identify lesions is of great value in clinical practice.”

About HY Medical

As a leading AI medical imaging company, HY Medical, through advanced technologies such as artificial intelligence and big data analysis, and leveraging SaaS services on the cloud, HY Medical solves data standardization, centralized storage, information interoperability, and various scenario based applications that can scale. The AI-assisted clinical diagnosis and treatment applications cover diagnosis and screening for more than ten diseases in addition to NCP, as well as support digital e-films applications and big data research applications.

Contact:
HY Medical
Person: Wendy Jia
Email: jiajingwen@huiyihuiying.com / marketing@huiyihuiying.com
Website: http://en.huiyihuiying.com/

Captiva Verde Land Corp – Corporate Update

Captiva Verde Land Corp. (CSE: PWR) (OTC: CPIVF) (the “Company” or “Captiva”), is pleased to announce the following updates for each of its business segments.

Mexico Pharmaceutical License

Captiva has started construction on its new manufacturing plant in Mexico to supply a wide range of psychoactive, heath and wellness, and narcotic medicines pursuant to our comprehensive pharmaceutical license to sell and distribute over 300 different types of psychoactive (psilocybin) and non-psychoactive (CBD) products. The plant will be finished in June and ready to produce in October of this year for positive accretive cash flow. Further, we have an arrangement to sell all of our products to the Union of Health Care Workers plus the larger group within the Union Federation, as a buying club of 1.2 Million members. Our products will be exceptional quality but priced for the Mexico market in the price range affordable in Mexico at a special discounted price for the benefit of the Union members and their families. This is a long term and sustainable strategy.

Solargram Farms

As stated in our previous news releases, one of the few remaining value propositions in the Cannabis business is to blow up the current status quo of high priced indoor cultivation with extremely low cost high quality outdoor grow. Last year, four (4) public companies produced only 3% of the legal Cannabis supply in Canada with outdoor grow operations. Their respective public disclosures list their total cost to produce at between 10 and 24 cents per gram vs $1.00 to $13.00 per gram for indoor grow, not including their destructively high G&A costs. Solargram was built to supply compassionate Cannabis at retail values well below that of the grey market, which grey market stubbornly controls 75% of the market share. The Solargram operations are almost complete and ready to commence licensed operations in early May with a very large ultra-low cost harvest ready for sale in October of this year.

Miss Envy

Miss Envy is an award winning health and wellness organization with the biggest selection of organic products in the market. Captiva has the world-wide rights outside of Canada. Captiva is currently developing the Miss Envy product line in Mexico to coordinate with the opening of our Mexican facility in June of this year. Miss Envy provides another one of the remaining value added propositions left in the industry, which is a world recognized brand with a huge following. Every time any other LP in the US or Canada sells a Cannabis product, they sell at a loss according to their public disclosures. This is not sustainable. Miss Envy offers a sustainable and profitable solution to the compassionate needs of the industry.

Meanwhile, Captiva is in the process of tweaking Miss Envy’s product lines to better appeal to Asian consumers and exploring opportunities to procure substantial sales from the Asian community with Miss Envy, where the products and themes are very well received. Updates will be released as they become available.

Sage Ranch, California

Captiva owns 50% of the sustainable and affordable one-thousand (1,000) housing unit Sage Ranch subdivision in Southern California. The project will have its final California Environmental Impact Report issued on March 4th for the 45 day public review period and then approval in front of the Planning Commission and City Counsel in June of this year. Upon approvals and completion of a 30 day appeal period, construction will commence at the annualized rate of 150 to 250 homes per year.

Summary

Captiva Verde is a highly efficient, nimble, extremely low overhead, high impact and sustainable socially responsible investment company with a multitude of high value projects that will all succeed due to a very loyal shareholder base and an execution oriented, sharply focused and dedicated management team.

On Behalf of the Board of Directors
“Jeffrey Ciachurski”

For further information, please contact:
Jeffrey Ciachurski
Chief Executive Officer and Director
Cell: (949) 903-5906
E-mail: westernwind@shaw.ca

Cautionary Note Regarding Forward Looking Information

This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52846

CloserStill Media launches Green World Asia, a sustainability-focused platform for business

SINGAPORE, Feb 27, 2020 – (ACN Newswire) – CloserStill Media is launching a new B2B event, Green World Asia, that will connect sustainability-driven innovations to senior decision-makers and their procurement chains from various industries. The show will focus on four key pillars across the exhibition showcase and conference programme: Utilities, Resources, Materials and Food Waste.

Green World Asia will debut at Marina Bay Sands in Singapore on November 18-19, 2020. The launch show is expected to attract over 5,000 industry delegates, featuring 100 exhibitors and 100 global expert speakers in a multi-stream conference programme over two days.

This expansion into the sustainability sector by CloserStill Media is driven by the global economic climate and an immense desire to help propel businesses, big and small, towards sustainable innovations and practices which result in commercial success for organisations, and the future of people & planet.

Green World Asia will serve as a practical access-to-market platform for organisations to connect, learn and be inspired by the vast possibilities of sustainable solutions. Visitors to Green World Asia can look forward to discovering the latest solutions that will address the challenges of creating sustainability-led practices whilst continuing to generate profit.

Commenting on the need for connecting organisations with vendors providing sustainable solutions, Green World Asia Co-founders James Murphy and Neil Halliday said, “Businesses are coming under immense pressure from internal and external stakeholders, to adopt green practices aligned with the United Nations Sustainable Development Goals. Many are struggling to get access to alternative solutions, or knowledge to build sustainability-driven strategies into the core of their business.”

“We are launching Green World Asia as a free-to-attend tradeshow to eliminate any barriers keeping companies from accessing practical knowledge and sourcing options.” they added.

Tom Peacock-Nazil, Founder of Seven Clean Seas, noted: “When it comes to sustainability, the world has needed less words and more action for decades. Finally, we are witnessing an upsurge in corporate responsibility and mass alignment of institutional capital to ESG principles. It’s great to see many players from many sectors today who are focusing on sustainability, and Green World Asia as a platform is well positioned and timed to act as the catalyst for connecting them.”

Innovation at the Heart of Sustainability

Participating at Green World Asia is Canada-based next-generation manufacturing and design company, ChopValue that turns used chopsticks into high-performance material for commercial and residential use. Mr. Felix Böck, founder and CEO of ChopValue said: “Participating in Green World Asia is a great opportunity for us to connect with business professionals in Asia and showcase the benefits of the circular economy versus linear economy.”

Another confirmed exhibitor, David Ward, founder of The Nurturing Company elaborated: “We are extremely excited about being a part of Green World Asia with both Bambooloo and CanO Water. It is a great pivotal moment for the region with sustainability and the environment being given the needed consideration across the spectrum, especially with the sustainability-driven policy and budget announcements made by the Singapore government recently. Green World Asia will be a great showcase for us to Singapore business, the region and the rest of the world.”

Strong Partner Networks

Green World Asia has already garnered positive attention in the sustainability landscape with multiple trade and media partners confirmed including: ASP, Circular Economy Asia, Circular Economy Club, Co-Creation Lab, Ecobahn, Eco-Business, Eco Film Festival Singapore, Engeco EnRupt, Green Is The New Black, Green In Future, Ocean Purpose Project, Orca Nation, Seven Clean Seas, The Incubation Network and Zero Waste SG.

Green World Asia is also a proud partner for The Liveability Challenge presented by Temasek Foundation, Eco-Business and Closed Loop Partners, and The Plastics Data Challenge by The Incubation Project.

Visitor registration will be open in July. Interested individuals can register for updates via the show website now.

Green World Asia 2020 will be held on 18 and 19 November at Marina Bay Sands Expo and Convention Centre in Singapore.

For more information, visit www.greenworldasia.com.

About CloserStill Media

CloserStill Media specialises in international professional events chiefly in the technology markets, across five global territories. Its portfolio includes some of the UK’s fastest-growing and award-winning events including Cloud Expo Europe and Data Centre World. Having delivered unparalleled quality and relevant audiences for all its exhibitions, CloserStill has been repeatedly recognised as a leading innovator with its teams and international events winning multiple awards in Europe and Asia including Best Marketing Manager – four times in succession – Best Trade Exhibition, Best Launch Exhibition, and Rising Star – two years in succession – among others.

For PR and Marketing Enquiry, please contact:
Ms Angie Eng
Director, Marketing and Partnerships
Tel: +65 6817 5811
Email: a.eng@closerstillmedia.com

Show Organiser:
CloserStill Media
72 Anson Road
#10-05, Anson House
Tel: +65 6817 5803
Email: gwa-marketing@closerstillmedia.com

Oxford Medical Case shows Chiropractics can ease Dizziness and Neck Pain

Just 4 weeks of chiropractic adjustment stimulating proprioception helps people deal with physical pain and annoying dizziness, according to a new case report at Oxford Medical Case Reports.

Neck muscles have numerous interactions with balance and visual centers. Neck problems can alter orientation in space and cause a disturbance of equilibrium. Cervicogenic dizziness is the dizziness associated neck pain and cervical disorders.

A 24-year-old office worker suffered from intermittent neck pain and dizziness for 2 years. She sought help at New York Medical Group and experienced dizziness by moving her head in different motion. All her blood tests, X-rays and MRI could not confirm her symptoms and medication only provided partial relief.

“Cervicogenic dizziness is a seemingly simple complaint for many working adults, but it can be a controversial diagnosis because there are no specific tests for doctors to use,” says corresponding author Eric Chun-Pu Chu, chairman of Chiropractic Doctors Association of Hong Kong and author of the study.

The sensory inputs from the neck play an important role in head-eye coordination and postural processes. For example, fish do not have necks and their head and trunk move as one unit in one direction without dizziness. But human has a highly developed sensory system to receive signals and move our trunk. Neck proprioception provides the necessary information about head movements relative to the trunk.

Determining the cause of dizziness is crucial to tailoring the most appropriate treatment protocol. Ruling out neurovascular etiologies is equally important before starting the manual therapy to prevent any untoward events in dizziness.

Chiropractic adjustment has been shown to have benefits in treating many conditions such as headaches and numbness. But Chu and colleagues wanted to know whether a patient with cervicogenic dizziness might benefit from correction of neck posture.

Researchers tested the patient with cervical adjustment and thermal ultrasound therapy, with emphasis on restoring mobility to stiff joints and relieving muscle tightness. Restoration of the cervical curvature was demonstrable on cervical radiographs in the 7th month.

The effect of chiropractic adjustment and ultrasound therapy was effective enough, they found, that both pain and dizziness resolved after 4 weeks of treatments. Researchers found significant relationship between cervical pain and lordosis angle of < 20 degrees. After 18 months, the patient remained free of drugs and symptoms.

The stimulation of cervical proprioceptors and normalization of the afferent input were the result of manual therapy, the author noted.

“The resolution of neck pain or dizziness suggests there may be clinical benefits to chiropractic care in cervicogenic dizziness,” Chu says.

Source: Chiropractic Doctors Association of Hong Kong
Study: doi.org/10.1093/omcr/omz115
Dr Eric Chun-Pu Chu
Chairman@cda.org.hk
Chiropractic Doctors Association of Hong Kong

Food Empire’s FY2019 Net Profit Jumps 44.9% to a Record US$25.7 Million

SINGAPORE – (ACN Newswire) – Food Empire Holdings Limited (“Food Empire”, together with its subsidiaries, the “Group”), announced today its financial results for the financial year ended 31 December 2019 (“FY2019”).

Financial Highlights

https://bit.ly/3c68AYk

Revenue by Markets

https://bit.ly/2uvEXic

Revenue for FY2019 was US$288.6 million, a yoy increase of 1.5% as compared to US$284.3 million revenue recorded in FY2018. This was mainly due to higher sales in local currency terms in the Group’s key markets partly offset by lower sales contribution from the Group’s South-East Asia market mainly due to rationalisation of underperforming markets and lower translated revenue resulting from depreciation of the Russian Ruble against the US dollar.

Gross profit was US$111.8 million, up 0.8% as compared to prior corresponding period, with gross profit margin of 38.7%.

Selling and marketing expenses were lower by US$6.3 million or 13.3% from US$47.8 million in FY2018 to US$41.5 million. The decrease was mainly due to rationalisation of underperforming markets partly offset by higher manpower cost.

General and administrative expenses decreased by US$1.5 million, from US$41.4 million in FY2018 to US$39.9 million. The decrease was mainly attributable to lower provision for doubtful debts partly offset by higher manpower cost.

Pursuant to the above, the Group’s net profit after tax for FY2019 was US$25.7 million, a yoy increase of 44.9%. Net profit margin was 2.7 percentage points (“pp”) higher, at 8.9% for FY2019.

For FY2019, the Group generated net operating cash flows of US$39.3 million mainly due to better performance and better working capital management, bringing its cash and cash equivalents to US$54.7 million.

The Board of Directors proposed a first and final dividend of 1 Singapore cent per ordinary share and a special dividend of 1 Singapore cent per ordinary share. The proposed first and final dividend and special dividend are subject to shareholders’ approval at the forthcoming Annual General Meeting scheduled for 23 April 2020. If approved, the first and final dividend and special dividend will be paid on 19 May 2020.

Commenting on the Group’s results, Mr. Tan Wang Cheow, Executive Chairman of Food Empire said, “FY2019 was a spectacular year for the Group and we are pleased to deliver yet another set of stellar results. The favorable outcome is a testament to the effectiveness of the Group’s strategies implemented to address identified problems and improve profitability. Moving ahead, we will remain focused on growing our key markets, streamlining our business operations and looking for strategic mergers & acquisitions opportunities to achieve sustainable growth.”

Outlook

The outbreak of the novel coronavirus (COVID-19) in China has since spread to a number of other countries. While efforts have been made to limit the advance of the disease, there is still substantial uncertainty over the duration and severity of COVID-19, which is expected to adversely affect global supply chains and threaten economic growth.

At this moment, the Group assessed that the health crisis is unlikely to have any direct or significant impact on its plans for the year. The Group expects business in its key consumer markets to remain resilient against the backdrop of a moderately acute and well-contained epidemic.

The Group will continue to invest in branding, product development and expanding distribution networks to capture greater consumer mindshare. It will also carry through corporate transformation initiatives to restructure business operations and streamline the organisation into a more cost efficient and sustainable global business.

The Group may face currency volatility in core markets such as Russia, Ukraine, Kazakhstan and CIS countries, which could impact the results of the Group.

Following the success of its first Non-Diary Creamer (“NDC”) plant, which is currently fully utilized, the Group has unveiled plans to commence the construction of a second NDC project on its existing plot of land located in the Iskandar region of Malaysia. The project will leverage on existing infrastructures and resources and is expected to take place over the next 24 months. When completed it will increase the existing capacity and offer a wider range of NDC products.

The Group’s Instant Freeze Dry Coffee plant in India is expected to be completed and will commence commercial production during the year.

The Group will take a cautious and targeted approach in evaluating M&A opportunities that are synergistic to the Group.

About Food Empire Holdings Limited (Bloomberg Code: FEH SP)

SGX Mainboard-listed Food Empire Holdings (Food Empire) is a global branding and manufacturing company in the food and beverage sector. Its products include instant beverage products, frozen convenience food, confectionery and snack food.

Food Empire’s products are exported to over 50 countries, in markets such as Russia, Ukraine, Kazakhstan, Central Asia, China, Indochina, the Middle East, Mongolia and the US. The Group has 24 offices (representative and liaison) worldwide. The Group operates 7 manufacturing facilities in Malaysia, India, Vietnam, Russia and Ukraine.

Food Empire’s products include a wide variety of beverages, such as regular and flavoured coffee mixes and cappuccinos, chocolate drinks and flavoured fruit teas. It also markets instant breakfast cereal, potato crisps and assorted frozen convenience foods.

Food Empire’s strength lies in its proprietary brands – including MacCoffee, Petrovskaya Sloboda, Klassno, Hyson, OrienBites and Kracks. MacCoffee – the Group’s flagship brand – has been consistently ranked as the leading 3-in-1 instant coffee brand in the Group’s core market of Russia, Ukraine and Kazakhstan. The Group employs sophisticated brand building activities, localised to match the flavour of the local markets in which its products are sold.

Since its public listing in 2000, Food Empire has won numerous accolades and awards including being recognised as one of the “Most Valuable Singapore Brands” by IE Singapore (now known as Enterprise Singapore), while MacCoffee has been ranked as one of “The Strongest Singapore Brands”. Forbes Magazine has twice named Food Empire as one of the “Best under a Billion” companies in Asia and the company has also been awarded one of Asia’s “Top Brand” by Influential Brands. For more information, please refer to: http://www.foodempire.com

Issued for and on behalf of Food Empire Holdings Limited.

by Financial PR Pte Ltd

Mr Ngo Yit Sung, yitsung@financialpr.com.sg

Ms Yong Jing Wen, jingwen@financialpr.com.sg

Tel: +65 6438 2990 Fax: +65 6438 0064

NanoViricides has filed Quarterly Report for period ending December 31, 2019

SHELTON, CT / ACCESSWIRE – (ACN Newswire) – NanoViricides, Inc. (NYSE American: NNVC), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed its quarterly report for its second quarter of financial year 2020 in a timely manner with the Securities and Exchange Commission. This press release should be read in conjunction with the Form 10-Q filed on February 14, 2020. The submission can be downloaded from the SEC website at: https://www.sec.gov/Archives/edgar/data/1379006/000110465920021930/tm205411-1_10q.htm.

The Company reported that it had approximately $1.0 Million (M) of current assets (cash, cash equivalents, and prepaid expenses), and current cash liabilities of approximately $1.4M excluding a recent mortgage (described below), as of December 31, 2019, the end of the reporting period. The net cash used in operating activities during the six months period was approximately $2.56M. The Company’s expenditures were in line with budget estimates. Shareholder equity stood at approximately $7.72M for the quarter (unaudited figures), primarily due to the asset value of its cGMP-capable manufacturing facility, R&D labs, and equipment, that it owns fully except for a $2 Million secured debt provision. The Company had no revenues. The Company has no long term debt.

The Company drew down $1.1M from a $2M non-convertible loan commitment secured by a mortgage on the Company’s facility provided by the Company’s founder and President, Anil R. Diwan, PhD. The mortgage is payable in full on March 31, 2021, with no payments due until then. Interest is payable only on amounts drawn by the Company.

In subsequent events, the Company has previously reported that it has raised approximately $8.625M in gross proceeds in an underwritten public offering, pursuant to an effective Form S-1 registration statement, comprising the sale of 2.5 million shares plus 375,000 shares of an underwriters over-allotment option at a price of $3 per share, with no warrants issued in the transaction. Aegis Capital Corp. acted as sole bookrunner for the offering. The net proceeds to the Company after underwriter’s commission and agreed upon customary fees and expenses were approximately $7.78 million, before deducting the Company’s legal and accounting expenses related to the Offering.

With these cash inflows, the Company believes it has sufficient funding for its planned expenditures for the ensuing year, based on estimated budgets including costs of certain clinical trials.

In subsequent events, the Company previously reported that it is working on developing a therapeutic drug for the treatment of the novel coronavirus 2019-nCoV, aka COVID-19. In 2014, the Company had engaged in drug discovery efforts against MERS coronavirus. The Company has reported that it has already found broad-spectrum virus-binding ligands that are expected to attack the virus at the same points that the virus uses to bind to its cognate cellular receptor, namely ACE-2 (angiotensin converting enzyme type 2), using molecular modeling based on known SARS-CoV and ACE2 interactions. COVID-19 shares significant similarity with, and uses the same cellular receptor as, SARS-CoV. The Company intends to perform initial testing of these drug candidates for safety and effectiveness in cell culture studies in its own BSL-2 virology laboratory at its Shelton campus, using low-threat coronavirus strains that have been normally circulating in human population.

The Company is working on developing necessary collaborations to take the program further should an effective drug candidate be identified. However, there can be no assurance that the Company will be successful in entering into such collaborations or that such collaborations will lead to an effective drug candidate. The Company does not currently have a license for the coronavirus field from TheraCour Pharma, Inc. (“TheraCour”), the licensor of the Company’s pharmaceutical candidates and a significant shareholder. Customarily, the Company enters into licensing agreements with TheraCour after a potential drug candidate is demonstrated to be likely effective against the virus. TheraCour has not previously denied any licenses sought by the Company.

The Company has experience developing broad-spectrum cellular receptor mimetics as virus-binding ligands for creating nanoviricide drugs. The Company has demonstrated this capability notably in its HerpeCide(TM) program, wherein nanoviricides based on the same antiviral ligand were found to be effective against at least three different kinds of herpesviruses, namely herpes simplex-1 (HSV-1), herpes simplex-2 (HSV-2), and, surprisingly, the non-simplex varicella zoster virus (VZV).

It is well recognized that development of vaccines takes a long time, and that vaccines can often be ineffective against viruses due to viral mutations that lead to emergence of resistant strains. It is also well recognized and well documented that monoclonal antibodies as antiviral drugs are very difficult to develop and often lead to emergence of resistant viral strains due to viral mutations.

In contrast, the Company believes that, its nanoviricide biomimetic technology platform has the potential to develop broad-spectrum antiviral drugs that viruses may not be able to escape due to mutations.

The Company continues to advance its first drug candidate, namely NV-HHV-101 skin cream, for the treatment of shingles rash as its first indication, towards human clinical trials. All of the planned IND-enabling Safety/Toxicology studies as well as other required non-clinical studies have been completed, and draft reports of various studies are being circulated between collaborating parties, as of the filing date. The Company anticipates receiving final cGLP reports for inclusion in our IND filing once the quality assurance processes are completed.

The Company has undertaken cGMP manufacture of the drug product, namely, NV-HHV-101 skin cream, indicated for the topical treatment of shingles rash, for supplying anticipated Phase I human clinical trials at its own facility. The Company has industry-leading internal expertise in the cGMP manufacture of complex nanomedicines drugs, right from simple starting materials to formulated drug products.

In a human skin patch organ culture model ex vivo, the Company has previously demonstrated the effectiveness and safety of topical NV-HHV-101 against VZV, the cause of shingles and chickenpox. These studies were conducted by Professor Jennifer Moffat at the Upstate Medical Center, SUNY Syracuse, NY. Professor Moffat has developed this model for pre-clinical evaluation of therapeutics against VZV, and is a well known expert in the field.

It is anticipated that the high effectiveness of our clinical drug candidate observed in this human skin model should be predictive of effectiveness in human clinical trials for topical dermal treatment of shingles.

Following shingles drug development, the Company anticipates developing drugs for HSV-1 cold sores and HSV-2 genital ulcers treatments using NV-HHV-101. The total market for our HerpeCide(TM) program drugs is estimated at several tens of billions of dollars because neither cures nor very effective treatments are available. The Company also has drug candidates in development at different pre-clinical stages in its Influenza and HIV drug programs. In addition, the Company has drug candidates against Dengue viruses, and was developing drugs against Ebola/Marburg viruses among others. The Company anticipates re-engaging these programs upon appropriate financing becoming available. Thus the Company has a rich and expanding pipeline of highly effective and safe drug candidates against a number of viral diseases.

NanoViricides is pioneering a unique platform for developing anti-viral drugs based on the “bind-encapsulate-destroy” principles. Viruses would not be able to escape a properly designed nanoviricide(R) drug by mutations because in doing so they would lose the ability to bind their cognate cellular receptor(s) and thus fail to infect productively, becoming incompetent.

There is a significant unmet medical need for the topical treatment of shingles rash. An effective therapy for shingles has been estimated to have a market size into several billions of dollars, if it reduces PHN incidence. An effective therapy for shingles rash reduction alone is estimated to have a market size of several hundred million dollars to low billion dollars. These market size estimates have taken into account the potential impact of the new Shingrix(R) GSK vaccine, assuming scaling up of their production in the 2024 time-frame, and the impact of the existing Zostavax(R) vaccine. Of note, the Shingrix vaccine has been found to cause significant, debilitating, side effects in as many as 15%-20% of the persons receiving it. Given that shingles is not a life-threatening disease (except under certain conditions), the uptake of such a vaccine with high incidence of adverse effects may be limited. Shingrix is not yet widely available.

The Company develops its class of drugs, that we call nanoviricides(R), using a platform technology. This approach enables rapid development of new drugs against a number of different viruses. A nanoviricide is a “biomimetic” – it is designed to “look like” the cell surface to the virus. The nanoviricide(R) technology enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody. In addition, the nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is the only technology in the world, to the best of our knowledge, that is capable of both (a) attacking extracellular virus, thereby breaking the reinfection cycle, and simultaneously (b) disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.

About NanoViricides

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The Company’s technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc.

Contact:

NanoViricides, Inc.

info@nanoviricides.com

Public Relations Contact:

MJ Clyburn

TraDigital IR

clyburn@tradigitalir.com

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. CMC refers to “Chemistry, Manufacture, and Controls”.

SOURCE: NanoViricides, Inc.

Tomini Shipping Approved and Registered for Listing on the NOTC

DUBAI, UAE, Feb 25, 2020 – (ACN Newswire) – Tomini Shipping, a world-class ship owner and operator in the dry bulk sector with operations in the UAE and India, has registered on the Norwegian Over the Counter market (the “NOTC”).

“Our ambition is to meet global transportation needs through expanding our fleet with the latest eco-friendly, technologically advanced vessels, which are able to deliver exceptional service to our global client network. With our experienced management team and highly motivated employees, Tomini Shipping is ready to lead the way,” says Imtiaz Shaikh, Chairman.

“The listing of Tomini on the NOTC is an exciting milestone. We believe that the broader exposure afforded by the NOTC will raise our visibility within the investment community and generate exposure of Tomini Shipping among institutional investors,” says Nitin Mehta, CEO.

Tomini Shipping will continue to look for new investment and acquisition opportunities that fit the Company’s existing business platform. The company has 12 Ultramax dry bulk carriers on the water, in addition to three Kamsarmax newbuilding orders with Taizhou Koaun in China, with delivery in 2020 and 2021.

NOTC is an unregulated marketplace owned and managed by the Oslo Stock Exchange.

About Tomini Shipping

Tomini Shipping is a world-class ship owner and operator in the dry bulk segment and majority-owned by Imtiaz Mohammad Shaikh, which for more than 65 years has been involved in every aspect of the shipping market including ownership, technical management and manning. Commercial management of Tomini’s fleet of modern vessels is handled through Alpina Chartering in Denmark, for the last 40 years, who are also partners.

Tomini Shipping has received multiple industry awards, most recently being recognized by the Maritime Standard. The company’s strategy focuses on being the most trusted partner in maritime services to their clients guided by their values and commitment to safety, corporate responsibility and sustainability. Further information can be found at https://tominishipping.com

For more information contact:

Sinead Brady

Head of Corporate Communications

+971 4 306 2000

ERB Secures $1 Billion Investment from McKinley Investment; Reimagines Global Financial Markets and Investor Risk in Southeast Asia

Tallinn, Estonia – (ACN Newswire) – ERB has attracted a $1 Billion investment from McKINLEY Investment, LLC. USA, and will begin to expand to other markets. Starting in Singapore, ERB will target markets in Thailand and Vietnam. McKINLEY Investment, LLC. USA, not widely known to the general public, establishes business partnerships with the world’s leading investment and government partners. However, the firm recently selected ERB as a major next-generation partner, and it is expected to continue expanding its base of investment for the general public.

ERB signed a PDG Financial Assurance Contract for $5 Billion with McKINLEY Investment, LLC. USA in 2019. This contract created a liquidity supply platform based on the world’s first PDG (Project Default Guarantee) program. Companies and investors are concerned about liquidity crisis and seeking a safe investment environment. While many platforms connect them, there is still a risk of “default” because investors have no information about where to invest and remain unsure of whether they will lose investments at any time. If investments fail, the company goes bankrupt and ERB returns the investor’s investment principal back by running the PDG program. With this program, innovation of the financial market has begun. Investors are prepared to invest in the spirit of “low risk, high returns,” and ERB is of great help to many companies, small and medium-sized, suffering from financial shortages due recent global economic recessions.

The following are seven Q&A’s interviewed with ERB Chairman Eom Meen.

Q1. ERB is said to have its headquarters in Dubai. What is your future business scope?

We have established direct branches in over 50 countries around the world since moving the ERB headquarters from Estonia to Dubai. Today, and in the future, we look forward to doing business in countries all over the world. However, we have immediate plans to concentrate efforts in Asian markets.

Q2. Why did you consider Asia to be your priority business area?

I have talked a lot, and sympathized a lot about, ERB doing business with partners from China and other Asian countries for a long time. I have the same aims as my Chinese friends and colleagues, and so it would be possible to create a synergy effect while doing business for prolonged growth and impact.

Q3. What direction do you pursue in terms of business?

What I consider first and foremost is ‘trust’ and, ultimately, ‘win-win’. The scope of ‘win-win’ is not exclusively between us, but between the investor and the investment, and between the same investors. The traditional zero-sum structure is out of date. We can design structures that can be win-win with better technologies and creative designs, and we no longer have to take others’ things and put them in our pockets. We lead both the investor and the investment to the way of profit through the PDG program, and there is no need to play the zero-sum game where investors take or are taken away. A safe place to invest is not based on speculation, probability game or gambling luck, but a real investment to make a profit.

Q4. What are the processes and features of PDG program?

Let me think from the point of view of the investor and the project organizer. The investor’s investment is provided to the project organizer’s project funds through ERB. If a business is successful, as everyone knows, everyone is happy to make money. But what if it fails? The project organizer tries to avoid the responsibility and the investor loses valuable money.

With ERB, it will never happen. When a project fails, we run ERB’s PDG program and return the investment principal back to the investor. We can give them a chance to try again by reviewing the progress and growth of the project.

Q5. If ERB runs the PDG program, may it lose money?

In fragments, it may seem so. However, it is not so. Our spending is an investment to attract new investors. Some investors may question whether they can get their investment back. If the investment goes to the investors through the PDG program, doubt will turn to conviction and develop into trust with ERB. I know the power of trust well. The investment platform trusted by the investor will be of absolute success. One or two small investors lead to large investors, and with large investors come global funds and the funds of government agencies seeking safe places to invest. As investments gather more and give greater guarantees, we will work to create a new investment ecosystem so investors cannot think of investment outside of ERB.

Q6. How was PDG funded?

McKINLEY Investment LLC, USA saw our platform, signed a PDG Financial Assurance Contract to increase the first $5 Billion to the final $20 Billion, deposited cash $5 Billion, and sent a Proof of Fund (POF). It took less than 10 days for this series of procedures to execute. They had a perfect understanding of our platform, even though it was a short time.

Son Masayoshi decided to invest $30 million in less than six minutes after Ma Yun began briefing on Alibaba, and he earned more than 4,000 times the Alibaba investment. McKINLEY, an investment company with decades of investment experience and success, has played a significant role in the growth and innovation of ERB.

Q7. What orientation does the ERO Platform have?

What the ERO Platform seeks is humanism. We will provide liquid funds to companies regardless of their credit ratings by considering innovativeness, future orientation, social contribution, and project growth value to support success for them and their projects. We are planning to establish a new standard in the international financial market by forming a virtuous circular investment environment of ‘low risk, high return’, and the consistent exercise of good influence.

Contact:

Evita Yoon

evitayoon@erbliga.com

https://erbliga.com

See: https://exrb.net/index, and https://www.mckinleyinvestment.com/forum/public-open-announcement/erb-is-known-worldwide-for-its-name-brand

Gaining more control over fuel cell membranes

Molecular orientation enhances proton conduction in proton-conductive polymers. (Copyright: Yuki Nagao)

More organization at the molecular level could improve the efficiency of membranes used in the hydrogen fuel cells that provide energy to electric cars and other industrial applications, according to a review published in the journal Science and Technology of Advanced Materials.

Hydrogen fuel cells are the energy-producing components of electric cars. To work, they need to be able to split hydrogen molecules into positively charged protons and negatively charged electrons. A particular type of membrane – a proton-conducting polymer membrane – is used for this purpose. It only allows protons to pass through it, while the electrons get circuited around the membranes to create the desired electric current. Protons are then transported along a thin ‘ionomer’ film and then into an electrochemical catalyst where electrons and protons rejoin.

Research has shown that proton transport through the thicker proton-conducting polymer membranes is better than it is in the thinner ionomer ones.

This second part of the proton transport process must be studied to improve fuel cell performance, says materials scientist Yuki Nagao of the Japan Advanced Institute of Science and Technology, who has been researching proton-conducting films for many years.

Using state-of-the-art technologies, he and others have been looking into the molecular structures of ionomer films and have been finding that the more organized they are internally, the better they conduct protons.

Some ionomer films commonly used in hydrogen fuel cells are made with perfluorinated sulfonic acid. The films can be placed on surfaces made from substances such as silicon oxide, magnesium oxide, or sputtered platinum or gold. Nagao has found that proton conductivity in these films depends on the type of surface and may affect fuel cell performance.

Molecules in another type of film, made from alkyl sulfonated polyimide, become more organized with water uptake. This property is the result of the material’s ability to enter a liquid crystal phase when solvent is added.”

“Developing a better understanding of these properties and their impacts on proton conduction will be important for clarifying proton conduction mechanisms,” explains Nagao.

Further research is needed to understand how to control molecular organization through the application of external magnetic fields, by employing their liquid crystal properties, or by developing hydrogen bond networks between polymer chains within the thin films. This could help lead to a variety of applications using highly proton-conductive polymer thin films.

Further information
Yuki Nagao
Japan Advanced Institute of Science and Technology
ynagao@jaist.ac.jp

Paper
https://doi.org/10.1080/14686996.2020.1722740

About Science and Technology of Advanced Materials Journal
Open access journal STAM publishes outstanding research articles across all aspects of materials science, including functional and structural materials, theoretical analyses, and properties of materials.

Shunichi Hishita
STAM Publishing Director
HISHITA.Shunichi@nims.go.jp

Press release distributed by ResearchSEA for Science and Technology of Advanced Materials.

Cloud & Cyber Security Expo Announces Rebrand to Cyber Security World Asia

SINGAPORE, Feb 19, 2020 – (ACN Newswire) – Cloud & Cyber Security Expo, a leading cybersecurity event in the Asia Pacific market, today announced the event’s rebranding in conjunction with its 5th edition happening this 14-15 October at Marina Bay Sands.

This initiative solidifies their position in the cybersecurity event industry by encompassing the larger scope of what cybersecurity entails in the digital transformation journey.

Event Manager, Dominic Pinfold commented, “Cyber Security World is a response to our delegates’ feedback in 2019, as their interests and needs go beyond just cloud security. With organisations of all sizes digitally transforming in 2020, the threat that underpins the integrity of this journey is cybersecurity.”

“Cyber Security World will be providing the tools for IT and IT Security professionals to carry out their critical mission. I am excited about the new features we have planned, and the additional value we can bring our delegates and sponsors as they attend the region’s largest and most comprehensive technology event series.”

The event will be co-located with 6 other shows – Cloud Expo Asia, Big Data & AI World, Smart IoT Singapore, Data Centre World, eCommerce Expo Asia and Technology for Marketing Asia. The rebranding initiative will piece the different co-located shows together as a comprehensive technology event series.

Aloysius Cheang, Board Director and Executive Vice President for Asia Pacific of Centre for Strategic Cyberspace + International Studies (CSCIS) remarked, “We’ve partnered with Cloud & Cyber Security Expo for many years now, and they are constantly evolving to keep up with the transforming cybersecurity landscape.”

“With this rebranding initiative, we’re excited to see how Cyber Security World will move beyond cloud security and bring more value to delegates this year. The CloserStill team has a successful technology event series and we will continue to be supportive to help deliver the best cybersecurity event in the Asia Pacific.”

Cyber Security World Asia’s sponsors and partners have played an essential role to its yearly success in the cybersecurity event landscape. Now they have a new mission – to work together to cater to a wider cybersecurity-focused audience.

About Cyber Security World Asia

Cyber Security World Asia is the industry-leading event in the world of digital protection. With its 5th edition happening this 14-15 October, Cyber Security World offers a unique platform for IT Security professionals responsible for cybersecurity to interact with leading suppliers and pioneers.

Maximise your brand exposure by sponsoring this industry-leading event. Learn more at www.cybersecurityworldasia.com

About CloserStill Media

CloserStill Media specialises in international professional events chiefly in the technology markets, across five global territories. Its portfolio includes some of the UK’s fastest-growing and award-winning events including Cloud Expo Europe and Data Centre World. Having delivered unparalleled quality and relevant audiences for all its exhibitions, CloserStill has been repeatedly recognised as a leading innovator with its teams and international events winning multiple awards in Europe and Asia including Best Marketing Manager – four times in succession – Best Trade Exhibition, Best Launch Exhibition, and Rising Star – two years in succession – among others.

For more information, visit www.closerstillmedia.com